Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
Invisible complications of sickle cell disease can result in a lack of understanding and proper care, says columnist.
The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...
Kanglin Biotechnology has raised $20 million in financing to advance the development of sickle cell gene therapy KL003.
Sites in Los Angeles and near San Francisco California are enrolling people with severe SCD for a trial to test a gene ...
Columnist Sylvia Amuta works to manage her anxiety after noticing that her own stress has a negative impact on her cousin ...
Columnist Oluwatosin Adesoye addresses some of the myths about blood transfusion and explains why it's important in managing ...